HealthDay News — With respect to seropositivity, aerosolized vaccination against measles is inferior to the subcutaneous vaccine, according to a study published in the New England Journal of Medicine.
“Aerosolized vaccine can be used as a needle-free method of immunization against measles,” noted Nicola Low, MD, of the University of Bern in Switzerland, and colleagues.
“Data on the immunogenicity of aerosolized vaccine against measles in children are inconsistent.”
To investigate the effectiveness of aerosolized vaccination, the investigators conducted an open-label noninferiority trial involving children aged 9.0 to 11.9 months in India who were eligible for the first dose of measles vaccine. Participants were randomized to receive a single dose of vaccine by means of aerosol inhalation (n=1,001) or subcutaneous injection (n=1,003). Follow-up data were available for 1,560 children in the per-protocol population.
At day 91, 85.4% of children in the aerosol group and 94.6% in the subcutaneous group were seropositive (difference of −9.2 percentage points). In the full set analysis and after imputation of missing results, the results were similar (85.4% in the aerosol group versus 94.7% in the subcutaneous injection group; difference of −9.3 percentage points).
No serious adverse events were observed as a result of the measles vaccination. Similar adverse-event profiles were seen for the two groups.
“Aerosolized vaccine against measles was immunogenic, but, at the prespecified margin, the aerosolized vaccine was inferior to the subcutaneous vaccine with respect to the rate of seropositivity,” concluded the researchers.